Table 3.
Results of univariate and multivariate analyses.
| Variables | Overall survival | Graft failure | ||||||
|---|---|---|---|---|---|---|---|---|
| sHR (95%CI) | p-value | asHR (95%CI) | p-value | OR (95%CI) | p-value | aOR (95%CI) | p-value | |
| Period (2018─2021) | 1.09 (0.54─2.24) | 0.801 | – | - | 1.46 (0.26─8.07) | 0.665 | – | - |
| Sex (male) | 0.82 (0.29─2.31) | 0.709 | – | – | 0.97 (0.10─9.37) | 0.986 | – | - |
| Prior HSCT | 0.83 (0.27─2.59) | 0.749 | – | – | - | - | – | - |
| HCT-CI ≥3 | 1.10 (0.60─2.05) | 0.758 | – | – | 1.5 (0.34─6.71) | 0.596 | – | – |
| Donor sex (male) | 0.67 (0.36─1.23) | 0.193 | – | – | 1.20 (0.26─5.59) | 0.818 | – | – |
| Iso-CMV sero-status | 0.75 (0.35─1.61) | 0.461 | – | - | 0.75 (0.12─4.29) | 0.747 | – | – |
| Source (bone marrow) | 1.12 (0.43─2.94) | 0.820 | – | - | 4.25 (0.63─28.7) | 0.138 | – | – |
| Reduced intensity conditioning | 1.87 (1.02─3.44) | 0.044 | 1.83 (0.99─3.68) | 0.052 | 3.6 (0.66─19.7) | 0.140 | – | – |
| Rituximab-based desensitization treatment | 1.03 (0.28─3.75) | 0.956 | 0.63 (0.21─1.84) | 0.396 | ||||
| Pregnancies (>2) | 0.97 (0.42─2.22) | 0.940 | - | - | 1.00 (0.15─6.42) | 1.000 | – | – |
| Major ABO incompatibility | 0.73 (0.20─2.73) | 0.649 | - | - | 1 (0.32─12.1) | 0.452 | – | – |
| CMV reactivation | 0.92 (0.45─1.92) | 0.839 | - | - | 0.78 (0.07─8.43) | 0.842 | – | – |
| DSA class (I vs. II vs. both) | 0.89 (0.47─1.69) 0.71 (0.29─1.74) |
0.732 0.464 |
- | - | 0.78 (0.12─44.84) 0.89 (0.14─5.58) |
0.791 0.904 |
– | – |
| DSA intensity >20,000 MFI at baseline | 2.92 (1.51─5.63) | 0.001 | 1.72 (1.09─2.94) | 0.046 | 3.33 (0.22─50.1) | 0.384 | – | – |
| Complement-fixation at baseline | 2.53 (0.44─14.6) | 0.300 | - | - | 0.57 (0.06─5.30) | 0.622 | – | – |
| DSA intensity >5,000 MFI at infusion | 1.13 (0.50─2.57) | 0.765 | - | - | 2.62 (0.49─13.9) | 0.257 | – | – |
| Intensity increase after infusion | 1.32 (0.46─3.82) | 0.599 | - | - | 24.67 (1.67─365) | 0.020 | 24.67 (1.67─365) | 0.020 |
Values are expressed as absolute numbers and percentages, and hazard/odds ratio and 95% confidence interval. Significant differences are shown in bold. Cox regression analysis was adjusted by the most significant clinical characteristics using a forward stepwise method (see Statistical Analysis section). Criteria for inclusion of covariates in the multivariate analysis were p-value < 0.1. 95%CI, 95% confidence interval; sHR, pseudo hazard ratio; asHR, adjusted pseudo hazard ratio; OR, odds ratio; aOR, adjusted odds ratio; p-value, level of significance. Significant values are marked in bold.